HuonsLab Presents Preclinical Efficacy of New Drug for Danjang Syndrome at US Conference

Poster Presentation of 'HLB1-006' at the Society of Parenteral and Enteral Nutrition
Awarded in Two Categories

Huons Lab recently announced on the 27th the preclinical efficacy results of the short bowel syndrome treatment new drug candidate 'HLB1-006' at the American Society for Parenteral and Enteral Nutrition (ASPEN) held in Las Vegas, USA.

A representative from Huons Lab is presenting a poster on the non-clinical efficacy results of 'HLB1-006' at the American Society for Parenteral and Enteral Nutrition (ASPEN) held in Las Vegas, USA. [Photo by Huons Lab]

Short bowel syndrome is a rare disease that occurs when the small intestine is shortened, leading to impaired digestion and absorption of nutrients. It is caused by congenital factors or surgical resection resulting in the loss of more than 50% of the entire small intestine, causing malnutrition. Treatments such as total parenteral nutrition (TPN) for more than 10 hours a day are required, making it difficult for patients to maintain a normal life.

HLB1-006 is a new peptide drug developed using Huons Lab's proprietary technology. Huons Lab explained that it is designed to maintain the activity of GLP-2 while simultaneously having some activity of GLP-1, showing higher therapeutic effects for short bowel syndrome compared to other candidate substances. It is being developed as a formulation with increased in vivo persistence, allowing administration once every two weeks or more.

At this conference, Huons Lab presented a poster detailing the efficacy of HLB1-006 according to dosing intervals and concentrations in mouse and rat animal models. Additionally, it was recognized for excellence and received awards in two categories: 'Best of ASPEN Abstracts: GI Topics' and 'International Poster of Distinction.'

Chae-young Lim, Executive Director of Huons Lab Bio Research Institute, said, "Many stakeholders related to short bowel syndrome showed great interest in the dual GLP-1/2 effects of HLB1-006, and there were many inquiries about when clinical trials would begin. Since we have confirmed definite efficacy and persistence in preclinical animal tests, we will do our best to prepare toxicity tests and clinical trials to obtain approval for an innovative new drug that can improve the quality of life for patients with short bowel syndrome."

Huons Lab, a subsidiary of Huons Global, is a company developing biopharmaceuticals and biosimilars, and is the third company in Korea to independently develop a biosimilar of Prolia.

This content was produced with the assistance of AI translation services.